Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens - Test2 - elhamkhani - TriplyDB

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens

http://www.wikidata.org/entity/Q24534391

about

Adverse effects of antiretroviral therapy for HIV infection Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.Development of a nursing intervention to facilitate optimal antiretroviral-treatment taking among people living with HIV.Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 HIV clinical trials are not enough.Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.Dendritic cells: key players in human herpesvirus 8 infection and pathogenesis.Trends in HIV prevalence, new HIV diagnoses, and mortality among adults with HIV who entered care in Ontario, 1996/1997 to 2009/2010: a population-based study.Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, pro Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients.Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay Adherence discourse among African-American women taking HAART Disparities in the burden of HIV/AIDS in Canada Fertility desire and intention of people living with HIV/AIDS in Tanzania: a call for restructuring care and treatment services.Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies.Predictors of early hospital readmission in HIV-infected patients with pneumonia.Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review.Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators.Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries HIV viral suppression in the era of antiretroviral therapy Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus.Rates of inappropriate antiretroviral prescription among injection drug users.Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia.Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program.Patient-related factors predicting HIV medication adherence among men and women with alcohol problems Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry.Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.

P2860

Q24617882-F7822D3B-B129-4332-95FC-131B32B60ED3 Q24656950-7C7677D5-0022-4EBF-81C3-7BE6968764C2 Q24792952-112DBDDE-A836-4525-A134-D893D9C4C085 Q24803596-899C3684-33FA-4ED8-8BDD-2EB7DCDA371A Q27021950-0D4858A3-D649-49FD-BE65-E59DC812DCAA Q27470167-95B6B5A4-55E6-4642-BDB7-CAE89012962B Q28487377-24DC11BE-5A55-408F-8FC8-4828BB2BFC4A Q33410098-B7FEBE00-B825-4CFB-B81A-3B71CE730FD5 Q33477968-F78732B4-C16B-4D0D-9919-23F63B3C31EA Q33761440-94AC5267-BC1D-4A81-8D3D-EFC3F594F645 Q33891656-2A01EC76-8595-47E2-B856-9D4A9C182DE1 Q33979107-6D9900E5-BE73-4E67-ABD1-9F7FBE7F14FD Q34030870-75F3566E-0D87-4177-8AB4-6FA503A09020 Q34070640-4690A332-839E-4395-BB33-0F4A43C27B55 Q34103593-C77C8882-EC81-49CA-9ECA-3FCADE352A07 Q34166791-502723A4-79F6-44C7-A868-A8A51376C067 Q34174009-3DB94A45-1C03-4E57-9FFF-47C91907B47A Q34193340-76FFC7C4-164B-4E64-9216-5AA60BF56CCC Q34249242-C1F19F84-2F44-41C3-954E-F9AFD4F31E3F Q34365075-E468EA38-30E0-4BB1-AFF0-307C56D14097 Q34399511-9CBA3BA7-AD54-48D2-A1DE-03329176B58E Q34405425-E063E4B8-6FA1-429A-9B67-B53522D4E618 Q34499532-10216B6E-7A2C-4C24-BF5B-B58C2E828730 Q34566872-5F8AE998-F783-48E9-B8E0-A0BDADCCB2D6 Q34605871-D542386A-9F36-42BE-8EBA-4C9BAD1F3EF8 Q34741352-E6C3726D-C653-4B0F-9C29-E6900F48C9D3 Q34954320-442C372C-6902-469B-AE73-45AAFFE541ED Q35022972-F47ECF13-9590-43CB-AD3B-3C81967582AC Q35057962-456EAA7E-A63C-4810-B55B-08266A11A1AC Q35059337-DB7873A9-1496-4F47-9169-2BFDCAACAC18 Q35119311-07CB0BF5-20EE-4108-AAFA-A84B0FD98E1D Q35186597-1CEC011B-A035-44D2-94F9-E16F24C4B08C Q35585411-F4C76074-E16B-4BE6-8665-C13AA6BAA982 Q35614736-FD4FCC4F-68C6-4528-AF35-038CCB0CF29D Q35618461-524488CD-232D-41BA-8B56-7E86D0553714 Q35623599-63BA35E7-13C5-4D96-8752-883DCE5E29B4 Q35758118-7E38C2ED-0288-4E25-980C-BCF69741AF19 Q35855263-7F67747D-FC10-47E8-90A6-15DF0CD7652A Q35859394-B128CF26-0F3F-4578-B672-22C22CCD444F Q35867142-5271412E-EC33-4532-810D-FA14E98F45CC

P2860

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens

http://www.wikidata.org/entity/Q24534391

description

1999 nî lūn-bûn

@nan

1999 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի մարտին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@ast

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en-gb

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@nl

type

label

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@ast

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en-gb

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@nl

prefLabel

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@ast

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en-gb

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@nl

P1433

Q24534391-D766E14E-0662-410B-A9B2-7369C0C0651C

P1476

Q24534391-E14A1DA0-755D-4CE6-AF3F-12AA40288981

P2093

Q24534391-44D95E84-F1C5-4077-9181-8A1141BEC1ED

Q24534391-511732E6-A4A0-4368-BE15-8DA08E2583FC

Q24534391-7FCD3421-D403-4BA2-A39C-DFF9F04C62D0

Q24534391-B4CB6147-3FB4-433C-BD89-33B326CF3750

Q24534391-B5A7087F-67E9-42CB-92A8-386847E2A524

Q24534391-E0388CBB-B140-4C8C-9B74-AE61F9E7F77C

Q24534391-E249A133-6FD2-4BDE-88C9-895E4AE39004

P2860

Q24534391-0D01AD9B-B5F3-43C0-AF5B-276A00799427

Q24534391-226027B5-7912-4DDA-8647-5DC8B1C343FA

Q24534391-23B12139-9D7F-453A-9FA3-0E13833148AE

Q24534391-4EE1E91A-286C-4C60-B0E3-7CF240ACB324

Q24534391-84810593-800D-4BEA-A6C3-8024EEDDC010

Q24534391-919326A1-8DAD-4078-9ADB-97700819F5D1

Q24534391-BDBE5B5C-7104-4BC0-919B-A7DBE3D1B46E

Q24534391-CF76B21C-5F99-4A99-BE8B-6BCDE2618E06

Q24534391-E5B8EE4A-5602-468E-B1F8-21D686347EAB

Q24534391-F0D9D2D4-BF6D-419B-AD4F-5A935A3B324A

P304

Q24534391-4FC752BE-9602-4DAD-8EF0-81DA8826BB93

P31

Q24534391-6A5D035D-F4A6-4EF1-83B4-2B40FEDEC98A

P3181

Q24534391-3E7B2641-B7C0-41C6-B234-B9CBF779C9A3

P407

Q24534391-4BA6A0C9-C359-40F2-9C28-7E9DFD61CC3A

P433

Q24534391-F691C642-8D5A-4D9F-A5A0-94D46BF26BEC

P478

Q24534391-B38A6DEF-0E51-4F67-93F0-C32A4B801849

P50

Q24534391-A5A85BA7-23D2-48EC-B3A6-E47DDB30F67C

P577

Q24534391-07E73AF0-8078-4C6E-B7AE-316FF4402DDA

P698

Q24534391-C112DA35-59CD-4E29-B768-875069D2D81A

P921

Q24534391-4963588D-2D73-4435-BF46-A75540E21D93

Q24534391-98797726-F4E3-4CF3-8F32-684B71D1BAEC

P932

Q24534391-DE85198E-D142-4A96-AF48-FE1A1CABB9F3

P3181

P1433

Canadian Medical Association Journal

P1476

Improved survival among HIV-in ...... e-drug antiretroviral regimens

@en

P2093

Craib KJ

http://www.w3.org/2001/XMLSchema#string

Hogg RS

http://www.w3.org/2001/XMLSchema#string

Kully C

http://www.w3.org/2001/XMLSchema#string

Montaner JS

http://www.w3.org/2001/XMLSchema#string

O'Shaughnessy MV

http://www.w3.org/2001/XMLSchema#string

Schechter MT

http://www.w3.org/2001/XMLSchema#string

Yip B

http://www.w3.org/2001/XMLSchema#string

P2860

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.

Decline in deaths from AIDS due to new antiretrovirals.

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Lower socioeconomic status and shorter survival following HIV infection.

Barriers to use of free antiretroviral therapy in injection drug users.

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

P304

659-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4468339

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

160

http://www.w3.org/2001/XMLSchema#string

P50

P577

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10102000

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

1230111

http://www.w3.org/2001/XMLSchema#string